ClinicalTrials.Veeva
Menu

Find clinical trials for Leukemia in San Francisco, CA

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Acute Myeloid Leukemia
B-Cell Chronic Lymphocytic Leukemia
Myeloid Leukemia
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Lymphoid Leukemia
Lymphoma
Myelodysplastic Syndromes

Leukemia trials near San Francisco, CA, USA:

Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma

The overarching objective of this study is to use novel precision medicine strategies based on inherited and acquired leukemia-specific geno...

Active, not recruiting
Acute Lymphoblastic Leukemia
Acute Lymphoblastic Lymphoma
Drug: Asparaginase Erwinia chrysanthemi (recombinant)-rywn
Drug: Thioguanine

Phase 2, Phase 3

St. Jude Children's Research Hospital
St. Jude Children's Research Hospital

Palo Alto, California, United States and 7 other locations

the first month following infusion of brexucabtagene autoleucel (Tecartus) in adults with relapsed or refractory B-cell acute lymphoblastic leukemia...

Active, not recruiting
Lymphoblastic Leukemia
Drug: Dasatinib

Phase 1

Stanford University
Stanford University

Palo Alto, California, United States

Phase 2 dose (RP2D) of revumenib in participants with acute leukemia.In Phase 2, participants will be enrolled in 3 indication-specific expa...

Enrolling
Acute Leukemia of Ambiguous Lineage
Mixed Phenotype Acute Leukemia
Drug: revumenib
Drug: cobicistat

Phase 1, Phase 2

Syndax Pharmaceuticals
Syndax Pharmaceuticals

Palo Alto, California, United States and 56 other locations

in future studies in study participants diagnosed with acute myeloid leukemia (AML), myelodysplastic syndromes with increased blasts grade 2...

Enrolling
Leukemia, Myeloid, Acute
Chronic Myelomonocytic Leukemia
Drug: Venetoclax Oral Tablet
Drug: Tuspetinib

Phase 1, Phase 2

Aptose Biosciences

Palo Alto, California, United States and 33 other locations

Recently updated

GDX012 is a novel cell therapy developed for the treatment of certain types of cancer, including Acute Myeloid Leukemia (AML). The main aims...

Active, not recruiting
Leukemia
Drug: GDX012
Drug: Chemotherapy Agents

Phase 1, Phase 2

Takeda
Takeda

Palo Alto, California, United States and 13 other locations

Eligible untreated patients with FLT3 acute myeloid leukemia (AML) between the ages of 18 and 70 will be randomized to receive gilteritinib ...

Active, not recruiting
Acute Myeloid Leukemia
Drug: Gilteritinib
Drug: Daunorubicin

Phase 2

PrECOG

Oakland, California, United States and 43 other locations

chemotherapy in induction-eligible patients with acute myeloid leukemia.This study involves the following:* Venetoclax and azacitidine (inve...

Enrolling
Acute Myeloid Leukemia
Drug: Venetoclax
Drug: Azacitidine

Phase 2

Mass General Brigham
Mass General Brigham

Palo Alto, California, United States and 8 other locations

in combination with Glasdegib in subjects with Acute Myelogenous Leukemia with myelodysplastic syndrome related changes or therapy-related a....

Active, not recruiting
Acute Myeloid Leukemia With Myelodysplasia-Related Changes
Acute Myelogenous Leukemia (AML) Due to Therapy
Drug: CPX-351
Drug: Glasdegib

Phase 2

University of California Irvine (UCI)
University of California Irvine (UCI)

San Francisco, California, United States and 3 other locations

A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-500, an oral FLT3 inhibitor, in adult patients with acute leukemia....

Active, not recruiting
Acute Myeloid Leukemia
Drug: BMF-500

Phase 1

Biomea Fusion

San Francisco, California, United States and 13 other locations

chemotherapy regimen for the treatment of B-cell acute lymphoblastic leukemia. Part 1 of the study will optimize the dose of study drug (rux...

Active, not recruiting
Leukemia
Drug: Methotrexate
Drug: Thioguanine

Phase 2

Incyte
Incyte

San Francisco, California, United States and 110 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems